Quoin Pharmaceuticals Ltd. Interest Expense On Lease Liabilities
Quoin Pharmaceuticals Ltd. (QNRX) reported Interest Expense On Lease Liabilities of ILS 88.00 thousand for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-29.
Discontinued › Expense Statement › Interest Expense
ifrs-full:InterestExpenseOnLeaseLiabilities · last filed 2021-03-29
ILS
| Period end | Interest Expense On Lease Liabilities 6 month | Interest Expense On Lease Liabilities 12 month |
|---|---|---|
| 2020-12-31 | 88.00K ILS 20-F · filed 2021-03-29 | |
| 2020-06-30 | 37.00K ILS 6-K/A · filed 2021-02-11 | |
| 2019-12-31 | 128.00K ILS 20-F · filed 2021-03-29 |
USD
| Period end | Interest Expense On Lease Liabilities 12 month |
|---|---|
| 2020-12-31 | $27.00K 20-F · filed 2021-03-29 |
| 2019-12-31 | $37.00K 20-F · filed 2020-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |